Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib vs physician's choice chemotherapy in gBRCA-mutated HER2-negative metastatic breast cancer
CTR20140906Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in breast cancer, sponsored by AstraZeneca. Started Dec 2014; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20140906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140906.